[144/A] Fulgent Genetics, Inc. SEC Filing

Rhea-AI Filing Summary

Fulgent Genetics, Inc. filed a Form 144/A reporting a proposed sale of 1,135 shares of common stock through Morgan Stanley Smith Barney with an approximate aggregate market value of $23,030.08, to be sold on 06/02/2025 on NASDAQ. The filer acquired 32,000 restricted shares on 02/28/2022 through equity compensation from Fulgent Genetics, Inc. The filing also discloses two recent sales on 05/27/2025 of 690 and 1,183 shares producing gross proceeds of $14,196.92 and $24,271.47 respectively. The notice includes the standard signer representation that no undisclosed material adverse information is known.

Insights

Securities Analyst

TL;DR Routine insider sale filing; transaction size is small relative to total shares outstanding and appears procedural.

The filing reports a proposed sale of 1,135 shares valued at roughly $23k against 30,443,595 shares outstanding, which is immaterial on a percentage basis. The shares were acquired via restricted stock vesting on 02/28/2022, indicating standard equity compensation monetization. Two recent dispositions on 05/27/2025 of 690 and 1,183 shares are disclosed with corresponding gross proceeds. There is no indication of material undisclosed information; this aligns with typical insider liquidity activity rather than corporate changes.

Corporate Governance Expert

TL;DR Disclosure follows Rule 144 conventions; the filing documents compliance and signer certification.

The notice identifies the broker, planned sale date, holdings acquired via equity compensation, and recent sales, fulfilling disclosure requirements. The signer represents no knowledge of undisclosed material adverse information and references potential 10b5-1 plan mechanics if applicable. From a governance perspective, the filing demonstrates procedural transparency but does not signal governance or control shifts.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144/A

144/A: Filer Information

Filer CIK
Filer CCC
Previous Accession Number Of The Filing
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144/A: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144/A: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza, 38th FL New York NY 10004	1135	23030.08	30443595	06/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144/A: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/28/2022	Resticted stock vest	Fulgent Genetics, Inc.			32000	02/28/2022	Equity compensation for services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144/A: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jian Xie C/O Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Monte CA 91731	Common Stock	05/27/2025	690	14196.92
Jian Xie C/O Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Monte CA 91731	Common Stock	05/27/2025	1183	24271.47

144/A: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144/A filed by Fulgent Genetics (FLGT) report?

The filing reports a proposed sale of 1,135 common shares via Morgan Stanley Smith Barney on 06/02/2025 with an aggregate market value of $23,030.08.

When and how were the securities being sold originally acquired?

The securities were acquired on 02/28/2022 as restricted stock that vested as equity compensation from Fulgent Genetics, Inc.

Has the filer recently sold any FLGT shares?

Yes. The filer sold 690 shares on 05/27/2025 for $14,196.92 and 1,183 shares on 05/27/2025 for $24,271.47.

On which exchange will the proposed sale occur?

The filing specifies the proposed sale will occur on NASDAQ.

Does the filing indicate any undisclosed material information about FLGT?

The signer represents they do not know of any material adverse information about the issuer that has not been publicly disclosed.